Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via AOL· 3 hours ago“This is the start of a banner year for our vaccine platform as we continue to advance mRNA...
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
CNBC· 14 hours agoModerna on Thursday posted a narrower-than-expected loss for the first quarter as the company's...
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline Amid Strategic Shifts
GuruFocus.com via Yahoo Finance· 13 hours agoStrategic Developments and Future Outlook Moderna's CEO, Stephane Bancel, emphasized the company's...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 13 hours agoModerna stock soared on Wednesday after its first-quarter earnings report sailed past Wall Street’s...
Moderna Stock Jumps After Scoring an Earnings Beat. Next Up? Its RSV Shot.
Barrons.com· 10 hours agoModerna reported first-quarter financial results Thursday that soundly beat Wall Street...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 14 hours agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...
Moderna beats estimates in Q1 2024, targets RSV vaccine launch in fall By Investing.com
Investing.com· 14 hours agoModerna Inc. (NASDAQ:MRNA) reported first-quarter earnings and revenue that came ahead of analyst...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 14 hours agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 7 hours agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
We Think Shareholders May Want To Consider A Review Of Moderna, Inc.'s (NASDAQ:MRNA) CEO...
Simply Wall St. via Yahoo Finance· 3 days ago(NASDAQ:MRNA) have been quite disappointing recently and CEO Stephane Bancel bears some...